Genexine Inc (095700)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Genexine Inc (095700)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH137914D
  • |
  • Pages: 32
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Genexine Inc (Genexine), formerly Genexine Co., Ltd. is a clinical stage biotechnology company that develops and commercialize of immunotherapeutics and next generation novel long-acting biologics. The company develops and conducts research on therapeutic vaccines for incurable diseases and next-generation antibody fusion protein drugs. It offers products for therapeutic areas such as orphans, cancers and immune disorders. Genexine provides GX-E2 for anemia; GX-G3 for neutropenia and GX-G6 for diabetes, among others. Its hyFc is a platform technology constructed to produce long-acting Fc fusion proteins by hybridizing IgD and IgG4. The company operates in Brazil, Turkey, India, Thailand, and Russia. Genexine is headquartered in Seongnam-si, South Korea.

Genexine Inc (095700)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Genexine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Genexine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Genexine Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Genexine Enters into Clinical Research Agreement with Merck 10

Tasly Pharma to Form Joint Venture with CBC SPVII and Genexine 10

Genexine to Form Joint Venture with Tasgen Bio-Tech 11

Licensing Agreements 12

Shanghai ChemoWanbang Biopharma Enters into Licensing Agreement with Genexine 12

Tasly Pharma Enters into Licensing Agreement with Genexine 12

Binex Enters Into Licensing Agreement With Genexine For Prolia 13

Equity Offering 14

Genexine Raises USD53 Million in Private Placement of Preferred Stock 14

Genexine to Raise USD17 Million in Private Placement of Shares 16

Genexine Completes Private Placement Of Common Stock For US$4.3 Million 17

Debt Offering 17

Genexine Raises USD17.8 Million in Private Placement of Bonds 17

Genexine Inc-Key Competitors 19

Key Employees 20

Locations And Subsidiaries 21

Head Office 21

Recent Developments 22

Product Approvals 22

Nov 16, 2016: Genexine Granted FDA Orphan Drug Designation for GX-H9 in Growth Hormone Deficiency 22

Clinical Trials 23

Apr 03, 2017: Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017 23

Jan 18, 2017: GX-G6 for Type 2 Diabetes, Receives Phase I IND Approval in Europe 24

Nov 21, 2016: Genexine Presents Phase 2 Interim Data of GX-H9 at JSPE 25

Sep 13, 2016: Genexine Announces Phase 2 Clinical Data of GX-H9 in ePoster presentation at ESPE 2016 26

Sep 09, 2016: Genexine to Present Phase 2 Clinical Data of GX-H9 at ESPE 2016 27

Sep 06, 2016: Genexine Presents Interim EU/KR Phase 2 Clinical Data of GX-H9 at ICE-CSE 2016 in Beijing 28

Jul 22, 2016: Genexine Confirms Possibility of Treatment in Cervicovaginal Tumor with Combination Therapy of hyFc-fused Interleukin-7 and HPV DNA Vaccine 29

Apr 08, 2016: Genexine Presents Positive Clinical Data for GX-H9 at ENDO 2016, Demonstrating a Potential for Semi-Monthly Administration 30

Mar 14, 2016: Genexine Clinical Study Data in Human Growth Hormone Selected for Late-Breaking Poster at ENDO 2016 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32

List of Figures

Genexine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Genexine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Genexine Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Genexine Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Genexine Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Genexine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Genexine Enters into Clinical Research Agreement with Merck 10

Tasly Pharma to Form Joint Venture with CBC SPVII and Genexine 10

Genexine to Form Joint Venture with Tasgen Bio-Tech 11

Shanghai ChemoWanbang Biopharma Enters into Licensing Agreement with Genexine 12

Tasly Pharma Enters into Licensing Agreement with Genexine 12

Binex Enters Into Licensing Agreement With Genexine For Prolia 13

Genexine Raises USD53 Million in Private Placement of Preferred Stock 14

Genexine to Raise USD17 Million in Private Placement of Shares 16

Genexine Completes Private Placement Of Common Stock For US$4.3 Million 17

Genexine Raises USD17.8 Million in Private Placement of Bonds 17

Genexine Inc, Key Competitors 19

Genexine Inc, Key Employees 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Genexine Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16263
Site License
USD 500 INR 32525
Corporate User License
USD 750 INR 48788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com